Report Code: 11385 | Available Format: PDF | Pages: 176
Hospital-Acquired Infection (HAI) Diagnostics Market by Product (Reagents and Consumables, Instruments), by Test Type (Immunoassay, Molecular Diagnostics, Urinalysis), by Application (Drug-Resistance, Disease), by Infection Type (UTIs, Surgical Site, Bloodstream, Gastrointestinal Hospital Acquired Pneumonia), by End User (Hospitals, Clinics, ASCs), by Geography (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Japan, China, Australia, South Korea, India, Brazil, Saudi Arabia, South Africa), Global Market Size, Share, Development, Growth, and Demand Forecast, 2016-2023
- Report Code: 11385
- Available Format: PDF
- Pages: 176
- Report Description
- Table of Contents
- Market Segmentation
- Request Free Sample
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Product
1.3.2 Market Segmentation by Test Type
1.3.3 Market Segmentation by Application
1.3.4 Market Segmentation by Infection Type
1.3.5 Market Segmentation by End User
1.3.6 Market Segmentation by Geography
1.3.7 Analysis Period
1.3.8 Market Data Reporting Unit
1.3.8.1 Value
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Reagents & consumables
4.1.1.2 Instruments
4.1.2 By Test Type
4.1.2.1 Immunoassay
4.1.2.2 Molecular diagnostics
4.1.2.3 Urinalysis
4.1.3 By Application
4.1.3.1 Drug-resistance testing
4.1.3.2 Disease testing
4.1.4 By Infection Type
4.1.4.1 Urinary tract infections (UTI)
4.1.4.2 Surgical site infections
4.1.4.3 Bloodstream infections
4.1.4.4 Gastrointestinal infections
4.1.4.5 Hospital acquired pneumonia
4.1.4.6 Others
4.1.5 By End User
4.1.5.1 Hospitals
4.1.5.2 Clinics
4.1.5.3 Ambulatory surgery centres (ASCs)
4.1.5.4 Others
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Growing geriatric population
4.2.1.2 Rising demand for HAIs diagnostics in emerging economies
4.2.1.3 Development of technologically advanced products
4.2.1.4 Impact analysis of drivers on market forecast
4.2.2 Restraints
4.2.2.1 Low prevalence of nosocomial infections in developed nations
4.2.2.2 Lack of awareness about HAIs
4.2.2.3 Impact analysis of restraints on market forecast
4.2.3 Opportunities
4.2.3.1 Rise in awareness initiatives by various organizations
4.3 Porter’s Five Forces Analysis
4.3.1 Bargaining Power of Buyers
4.3.2 Bargaining Power of Suppliers
4.3.3 Intensity of Rivalry
4.3.4 Threat of New Entrants
4.3.5 Threat of Substitutes
Chapter 5. Global Market Size and Forecast
5.1 By Product
5.2 By Test Type
5.3 By Application
5.4 By Infection Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.2 By Test Type
6.3 By Application
6.4 By Infection Type
6.5 By End User
6.6 By Country
6.6.1 U.S. Hospital-Acquired Infection Diagnostics Market
6.6.1.1 By product
6.6.1.2 By test type
6.6.1.3 By application
6.6.1.4 By infection type
6.6.1.5 By end user
6.6.2 Canada Hospital-Acquired Infection Diagnostics Market
6.6.2.1 By product
6.6.2.2 By test type
6.6.2.3 By application
6.6.2.4 By infection type
6.6.2.5 By end user
6.6.3 Mexico Hospital-Acquired Infection Diagnostics Market
6.6.3.1 By product
6.6.3.2 By test type
6.6.3.3 By application
6.6.3.4 By infection type
6.6.3.5 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.2 By Test Type
7.3 By Application
7.4 By Infection Type
7.5 By End User
7.6 By Country
7.6.1 Germany Hospital-Acquired Infection Diagnostics Market
7.6.1.1 By product
7.6.1.2 By test type
7.6.1.3 By application
7.6.1.4 By infection type
7.6.1.5 By end user
7.6.2 France Hospital-Acquired Infection Diagnostics Market
7.6.2.1 By product
7.6.2.2 By test type
7.6.2.3 By application
7.6.2.4 By infection type
7.6.2.5 By end user
7.6.3 U.K. Hospital-Acquired Infection Diagnostics Market
7.6.3.1 By product
7.6.3.2 By test type
7.6.3.3 By application
7.6.3.4 By infection type
7.6.3.5 By end user
7.6.4 Italy Hospital-Acquired Infection Diagnostics Market
7.6.4.1 By product
7.6.4.2 By test type
7.6.4.3 By application
7.6.4.4 By infection type
7.6.4.5 By end user
7.6.5 Spain Hospital-Acquired Infection Diagnostics Market
7.6.5.1 By product
7.6.5.2 By test type
7.6.5.3 By application
7.6.5.4 By infection type
7.6.5.5 By end user
Chapter 8. APAC Market Size and Forecast
8.1 By Product
8.2 By Test Type
8.3 By Application
8.4 By Infection Type
8.5 By End User
8.6 By Country
8.6.1 Japan Hospital-Acquired Infection Diagnostics Market
8.6.1.1 By product
8.6.1.2 By test type
8.6.1.3 By application
8.6.1.4 By infection type
8.6.1.5 By end user
8.6.2 China Hospital-Acquired Infection Diagnostics Market
8.6.2.1 By product
8.6.2.2 By test type
8.6.2.3 By application
8.6.2.4 By infection type
8.6.2.5 By end user
8.6.3 Australia Hospital-Acquired Infection Diagnostics Market
8.6.3.1 By product
8.6.3.2 By test type
8.6.3.3 By application
8.6.3.4 By infection type
8.6.3.5 By end user
8.6.4 South Korea Hospital-Acquired Infection Diagnostics Market
8.6.4.1 By product
8.6.4.2 By test type
8.6.4.3 By application
8.6.4.4 By infection type
8.6.4.5 By end user
8.6.5 India Hospital-Acquired Infection Diagnostics Market
8.6.5.1 By product
8.6.5.2 By test type
8.6.5.3 By application
8.6.5.4 By infection type
8.6.5.5 By end user
Chapter 9. LAMEA Market Size and Forecast
9.1 By Product
9.2 By Test Type
9.3 By Application
9.4 By Infection Type
9.5 By End User
9.6 By Country
9.6.1 Brazil Hospital-Acquired Infection Diagnostics Market
9.6.1.1 By product
9.6.1.2 By test type
9.6.1.3 By application
9.6.1.4 By infection type
9.6.1.5 By end user
9.6.2 Saudi Arabia Hospital-Acquired Infection Diagnostics Market
9.6.2.1 By product
9.6.2.2 By test type
9.6.2.3 By application
9.6.2.4 By infection type
9.6.2.5 By end user
9.6.3 South Africa Hospital-Acquired Infection Diagnostics Market
9.6.3.1 By product
9.6.3.2 By test type
9.6.3.3 By application
9.6.3.4 By infection type
9.6.3.5 By end user
Chapter 10. Competitive Landscape
10.1 Market Share Analysis of Key Players
10.2 Global Strategic Developments of Key Players
10.2.1 Mergers and Acquisitions
10.2.2 Product Launch and Approvals
10.2.3 Partnerships
Chapter 11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Business Overview
11.1.2 Product and Service Offerings
11.2 AstraZeneca plc
11.2.1 Business Overview
11.2.2 Product and Service Offerings
11.3 Bayer AG
11.3.1 Business Overview
11.3.2 Product and Service Offerings
11.4 Becton, Dickinson and Company
11.4.1 Business Overview
11.4.2 Product and Service Offerings
11.5 Daiichi Sankyo Co. Ltd.
11.5.1 Business Overview
11.5.2 Product and Service Offerings
11.6 Danaher Corporation
11.6.1 Business Overview
11.6.2 Product and Service Offerings
11.7 Hologic Inc.
11.7.1 Business Overview
11.7.2 Product and Service Offerings
11.8 Johnson & Johnson
11.8.1 Business Overview
11.8.2 Product and Service Offerings
11.9 OpGen, Inc.
11.9.1 Business Overview
11.9.2 Product and Service Offerings
11.1 F. Hoffmann La-Roche AG
11.10.1 Business Overview
11.10.2 Product and Service Offerings
Chapter 12. Appendix
12.1 Abbreviations
12.2 Sources and References
12.3 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 5 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 6 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016 – 2023)
TABLE 7 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 8 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 9 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY REGION, $M (2016–2023)
TABLE 10 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 11 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 12 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 13 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 14 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 15 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
TABLE 16 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 17 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 18 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 19 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 20 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 21 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 22 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 23 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 24 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 25 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 26 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 27 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016-2023)
TABLE 28 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 29 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 30 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 31 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 32 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 33 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 34 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 35 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 36 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
TABLE 37 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 38 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 39 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 40 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 41 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 42 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 43 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 44 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 45 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 46 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 47 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 48 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 49 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 50 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 51 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 52 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 53 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 54 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 55 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 56 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016 – 2023)
TABLE 57 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 58 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 59 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 60 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 61 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 62 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 63 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 64 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 65 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 66 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 67 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
TABLE 68 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 69 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 70 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 71 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 72 JAPAN. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 73 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 74 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 75 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 76 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 77 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 78 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 79 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 80 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 81 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 82 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 83 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 84 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 85 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 86 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 87 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 88 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 89 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 90 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 91 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 92 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 93 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 94 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 95 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 96 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 97 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 98 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
TABLE 99 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 100 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 101 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 102 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 103 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 104 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 105 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 106 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 107 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 108 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 109 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
TABLE 110 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
TABLE 111 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
TABLE 112 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
TABLE 113 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
TABLE 114 ABBOTT LABORATORIES – AT A GLANCE
TABLE 115 ASTRAZENECA PLC - AT A GLANCE
TABLE 116 BAYER AG – AT A GLANCE
TABLE 117 BECTON, DICKINSON AND COMPANY – AT A GLANCE
TABLE 118 DAIICHI SANKYO CO., LTD. – AT A GLANCE
TABLE 119 DANAHER CORPORATION – AT A GLANCE
TABLE 120 HOLOGIC INC. - AT A GLANCE
TABLE 121 JOHNSON & JOHNSON - AT A GLANCE
TABLE 122 OPGEN, INC. – AT A GLANCE
TABLE 123 F. HOFFMANN LA-ROCHE AG – AT A GLANCE
LIST OF FIGURES
FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 7 DATA TRIANGULATION APPROACH
FIG 8 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SUMMARY
FIG 9 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION
FIG 10 PORTER’S FIVE FORCES ANALYSIS
FIG 11 BARGAINING POWER OF BUYERS
FIG 12 BARGAINING POWER OF SUPPLIERS
FIG 13 INTENSITY OF RIVALRY
FIG 14 THREAT OF NEW ENTRANTS
FIG 15 THREAT OF SUBSTITUTES
FIG 16 SNAPSHOT OF GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET (2016)
FIG 17 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
FIG 18 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
FIG 19 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
FIG 20 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
FIG 21 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
FIG 22 WORLDWIDE MAJOR MARKETS FOR HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS
FIG 23 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT
FIG 24 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
FIG 25 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
FIG 26 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
FIG 27 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
FIG 28 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
FIG 29 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
FIG 30 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT
FIG 31 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
FIG 32 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
FIG 33 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
FIG 34 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
FIG 35 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
FIG 36 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
FIG 37 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT
FIG 38 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
FIG 39 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
FIG 40 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
FIG 41 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
FIG 42 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
FIG 43 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
FIG 44 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT
FIG 45 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)
FIG 46 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)
FIG 47 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)
FIG 48 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)
FIG 49 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)
FIG 50 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)
FIG 51 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SHARE OF KEY PLAYERS (2016)
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to Analyst
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws